EPIX Pharmaceuticals 8-K 2006
Documents found in this filing:
WASHINGTON, DC 20549
CURRENT REPORT PURSUANT
Date of report (Date of earliest event reported): January 10, 2006
EPIX Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction of Incorporation)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
On Tuesday, January 10, 2006, EPIX Pharmaceuticals, Inc.s (EPIX) Interim Chief Executive Officer, Michael J. Astrue, delivered a presentation at the 8th Annual Needham & Company, LLC Growth Conference at the Palace Hotel in New York City. The presentation was webcast live and included an update on the status of EPIX clinical, regulatory, financial and business development activities. An archived version of the webcast will be available for ninety days and can be accessed through the Investor Relations page of EPIX website, www.epixpharma.com.
A copy of the slides used in the presentation are attached to this Current Report on Form 8-K as Exhibit 99.1 and are incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) The following exhibits are furnished with this report:
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.